Quick Answer
Lyell Immunopharma, Inc. reported Total Assets of $340.05 million for the year ending 2025.
- Lyell Immunopharma, Inc. showed a decrease of -30.7% in Total Assets from 2024 to 2025.
- This data is from Lyell Immunopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $1.23 billion | Q3 2021: $1.20 billion | Q1 2022: $1.07 billion | Q2 2022: $1.02 billion | Q3 2022: $977.27 million | Q1 2023: $880.45 million | Q2 2023: $835.35 million | Q3 2023: $794.99 million | Q1 2024: $694.22 million | Q2 2024: $654.14 million | Q3 2024: $619.22 million | Q1 2025: $429.80 million | Q2 2025: $385.45 million | Q3 2025: $407.97 million.
- Over the full 6 years of available data (2020 to 2025), Lyell Immunopharma, Inc.'s Total Assets has declined by 62.6%.
- Historical annual values: Fiscal year 2025: $340.05 million | Fiscal year 2024: $490.86 million | Fiscal year 2023: $750.03 million | Fiscal year 2022: $937.56 million | Fiscal year 2021: $1.13 billion | Fiscal year 2020: $908.28 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: